Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators declaring it safe

A new pioneering Alzheimer's drug has been rejected for widespread use in the NHS in England. The announcement comes as the UK's medicines regulator said that donanemab could be licenced for use in the UK.

Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on Wednesday, signalling that patients are unlikely to get access following approval by the country's medicines regulator.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.

Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns - Campaigners say decision is ‘frustrating setback’ for people living with disease